1. Home
  2. NOAH vs JANX Comparison

NOAH vs JANX Comparison

Compare NOAH & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NOAH

Noah Holdings Limited

HOLD

Current Price

$12.01

Market Cap

754.2M

Sector

Finance

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$13.20

Market Cap

890.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOAH
JANX
Founded
2005
2017
Country
China
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
754.2M
890.8M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
NOAH
JANX
Price
$12.01
$13.20
Analyst Decision
Buy
Buy
Analyst Count
2
12
Target Price
$10.75
$57.36
AVG Volume (30 Days)
120.4K
1.6M
Earning Date
03-24-2026
03-09-2026
Dividend Yield
4.85%
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
$355,222,638.00
$10,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.79
N/A
P/E Ratio
$12.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.67
$12.12
52 Week High
$12.84
$38.42

Technical Indicators

Market Signals
Indicator
NOAH
JANX
Relative Strength Index (RSI) 63.56 41.85
Support Level $11.77 $12.74
Resistance Level $12.13 $13.61
Average True Range (ATR) 0.42 0.67
MACD 0.01 0.09
Stochastic Oscillator 82.67 38.01

Price Performance

Historical Comparison
NOAH
JANX

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: